Inventor · disambiguated record
Carol Elaine O'Hear
Also filed as: O'HEAR CAROL E · O'HEAR CAROL ELAINE
5 granted patents·5 pending applications·1 citations·filing 2005–2025
63Inventor score
Files withGENENTECH INC7ARROWSMITH TECHNOLOGIES CORP1FOOTE JEFFERSON1ST JUDE CHILDRENS RES HOSPITAL INC1
Top patents by PatentIndex Score
10 records- 0177US12351643B2Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2021·Granted Jul 8, 2025·1 cites·80 claims
- 0267US12291575B2Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotinGENENTECH INC·Filed 2022·Granted May 6, 2025·0 cites·43 claims
- 0364US2025250353A1Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotinGENENTECH INC·Filed 2025·Application pending·0 cites
- 0455US2022380466A1Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodiesGENENTECH INC·Filed 2022·Application pending·0 cites
- 0553US2023416391A1Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patientsGENENTECH INC·Filed 2023·Application pending·0 cites
- 0651US12492261B2Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodiesGENENTECH INC·Filed 2021·Granted Dec 9, 2025·0 cites·42 claims
- 0749US2023190932A1Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomideGENENTECH INC·Filed 2022·Application pending·0 cites
- 0847US12053490B2Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cellsST JUDE CHILDRENS RES HOSPITAL INC·Filed 2018·Granted Aug 6, 2024·0 cites·23 claims
- 0941US9173958B2Antibody buffering of a ligand in vivoFOOTE JEFFERSON·Filed 2005·Granted Nov 3, 2015·0 cites·21 claims
- 1036US2016082105A1Antibody Buffering of a Ligand in VivoARROWSMITH TECHNOLOGIES CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Carol Elaine O'Hear files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →